Consistency and safety of cell banks for research and clinical use: Preliminary analysis of fetal skin banks

Cell Transplantation

Volumn 16, Issue 7, 2007, Pages 675-684

  Quintin, Aurelie ^a,b   Hirt Burri, Nathalie ^a   Scaletta, Corinne ^c   Schizas, Constantin ^c   Pioletti, Dominique P ^b   Laurent Applegate, Lee Ann ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b EPFL   (Switzerland)

^c Hopital Orthopedique de la Suisse Romande   (Switzerland)

Author keywords

Cell banking; Fetal cells; Fibroblasts; Safety; Tissue engineering

Indexed keywords

BETA ACTIN; MATRIX METALLOPROTEINASE 14; NEURITE PROMOTING FACTOR; OSTEOPROTEGERIN; PLEIOTROPHIN; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ARTICLE; CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CELL THERAPY; CELL TYPE; CLINICAL RESEARCH; CONTROLLED STUDY; FEMALE; FETUS; FETUS CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; ORGAN DONOR; PRIORITY JOURNAL; TISSUE ENGINEERING; ANIMAL; CULTURE TECHNIQUE; HEALTH CARE FACILITY; HISTOLOGY; SKIN; SKIN TRANSPLANTATION; STANDARD; TRANSPLANTATION;

ANIMALS; CELL CULTURE TECHNIQUES; CELLS, CULTURED; FEMALE; FETUS; HUMANS; MALE; SKIN; SKIN TRANSPLANTATION; TISSUE AND ORGAN PROCUREMENT; TISSUE BANKS;

EID: 38749134546     PISSN: 09636897     EISSN: None     Source Type: Journal    
DOI: 10.3727/000000007783465127     Document Type: Article

References (34)

1. Barry, F. P.; Murphy, J. M. Mesenchymal stem cells: Clinical applications and biological characterization. Int. J. Biochem. Cell Biol. 36(4):568-584; 2004.
2. Bhattacharya, N. Fetal cell/tissue therapy in adult disease: A new horizon in regenerative medicine. Clin. Exp. Obstet. Gynecol. 31(3): 167-173; 2004.
3. Bianco, P.; Robey, P. G. Stem cells in tissue engineering. Nature 414(6859): 118-121; 2001.
4. Bullard, K. M.; Longaker, M. T.; Lorenz, H. P. Fetal wound healing: current biology. World J. Surg. 27(1):54-61; 2003.
5. Carter, D. M.; Lin, A. N.; Varghese, M. C.; Caldwell, D.; Pratt, L. A.; Eisinger, M. Treatment of junctional epidermolysis bullosa with epidermal autografts. J. Am. Acad. Dermatol. 17(2 Pt. 1):246-250; 1987.
6. CPMP/ICH. Note for guidance on quality of biotechnological products: Derivation and characterisation of cell substrates used for production of biotechnological/biological products. CPMP/ICH/294/95; 2001.
7. CPMPACH. Note for guidance on the use of bovine serum in the manufacture of human biological medicinal products. CPMP/BWP/1793/02; 2002.
8. De Buys Roessingh, A. S.; Hohlfeld, J.; Scaletta, C.; Hirt-Burri, N.; Gerber, S.; Hohlfeld, P.; Gebbers, J. O.; Applegate, L. A. Development, characterization, and use of a fetal skin cell bank for tissue engineering in wound healing. Cell Transplant. 15(8-9):823-834; 2006.
9. Eaglstein, W. H.; Falanga, V. Tissue engineering and the development of Apligraf a human skin equivalent. Adv. Wound Care 11(4 Suppl.):1-8; 1998.
10. Enserink, M. Biomedicine. Selling the stem cell dream. Science 313(5784):160-163; 2006.
11. Fimiani, M.; Pianigiani, E.; Di Simplicio, F. C.; Sbano, P.; Cuccia, A.; Pompella, G.; De Aloe, G.; Petraglia, F. Other uses of homologous skin grafts and skin bank bioproducts. Clin. Dermatol. 23(4):396-402; 2005.
12. Gallico, 3rd, G. G.; O'Connor, N. E.; Compton, C. C.; Remensnyder, J. P.; Kehinde, O.; Green, H. Cultured epithelial autografts for giant congenital nevi. Plast. Reconstr. Surg. 84(1):1-9; 1989.
13. Giannoni, P.; Pagano, A.; Maggi, E.; Arbico, R.; Randazzo, N.; Grandizio, M.; Cancedda, R.; Dozin, B. Autologous chondrocyte implantation (ACI) for aged patients: Development of the proper cell expansion conditions for possible therapeutic applications. Osteoarthritis Cartilage 13(7):589-600; 2005.
14. Hasegawa, T.; Suga, Y.; Mizoguchi, M.; Ikeda, S.; Ogawa, H.; Kubo, K.; Matsui, H.; Kagawa, S.; Kuroyanagi, Y. Clinical trial of allogeneic cultured dermal substitute for the treatment of intractable skin ulcers in 3 patients with recessive dystrophic epidermolysis bullosa. J. Am. Acad. Dermatol. 50(5):803-804; 2004.
15. Heinonen, M.; Oila, O.; Nordstrom, K. Current issues in the regulation of human tissue-engineering products in the European Union. Tissue Eng. 11(11-12):1905-1911; 2005.
16. Hirakawa, K.; Jacobs, J. J.; Urban, R.; Saito, T. Mechanisms of failure of total hip replacements: lessons learned from retrieval studies. Clin. Orthop. Relat. Res. 420:10-17; 2004.
17. Hohlfeld, J.; de Buys Roessingh, A.; Hirt-Burri, N.; Chaubert, P.; Gerber, S.; Scaletta, C.; Hohlfeld, P.; Applegate, L. A. Tissue engineered fetal skin constructs for paediatric burns. Lancet 366(9488):840-842; 2005.
18. Horch, R. E.; Kopp, J.; Kneser, U.; Beier, J.; Bach, A. D. Tissue engineering of cultured skin substitutes. J. Cell. Mol. Med. 9(3):592-608; 2005.
19. Jacobs, J. J.; Hallab, N. J.; Urban, R. M.; Wimmer, M. A. Wear particles. J. Bone Joint Surg. Am. 88(Suppl. 2):99-102; 2006.
20. Klimanskaya, I.; Chung, Y.; Meisner, L.; Johnson, J.; West, M. D.; Lanza, R. Human embryonic stem cells derived without feeder cells. Lancet 365(9471):1636-1641; 2005.
21. Kozak, R. W.; Golker, C. F.; Stadler, P. Transmissible spongiform encephalopathies (TSE): Minimizing the risk of transmission by biological/biopharmaceutical products: An industry perspective. Dev. Biol. Stand. 88:257-264; 1996.
22. Mire-Sluis, A. R. Progress in the use of biological assays during the development of biotechnology products. Pharm. Res. 18(9):1239-1246; 2001.
23. Montjovent, M. O.; Burri, N.; Mark, S.; Federici, E.; Scaletta, C.; Zambelli, P. Y.; Hohlfeld, P.; Leyvraz, P. F.; Applegate, L. L.; Pioletti, D. P. Fetal bone cells for tissue engineering. Bone 35(6):1323-1333; 2004.
24. Oskouian, R. J.; Whitehill, R.; Samii, A.; Shaffrey, M. E.; Johnson, J. P.; Shaffrey, C. I. The future of spinal arthroplasty: A biomaterial perspective. Neurosurg. Focus 17(3):E2; 2004.
25. Osswald, S. S.; Elston, D. M.; Vogel, P. S. Giant right plantar keloid treated with excision and tissue-engineered allograft. J. Am. Acad. Dermatol. 48(1):131-134; 2003.
26. Pioletti, D. P.; Montjovent, M. O.; Zambelli, P. Y.; Applegate, L. Bone tissue engineering using foetal cell therapy. Swiss Med. Wkly. 136(35-36):557-560; 2006.
27. Preti, R. A. Bringing safe and effective cell therapies to the bedside. Nat. Biotechnol. 23(7):801-804; 2005.
28. Shakespeare, P. G. The role of skin substitutes in the treatment of burn injuries. Clin. Dermatol. 23(4):413-418; 2005.
29. Vats, A.; Bielby, R. C.; Tolley, N. S.; Nerem, R.; Polak, J. M. Stem cells. Lancet 366(9485):592-602; 2005.
30. Vats, A.; Tolley, N. S.; Bishop, A. E.; Polak, J. M. Embryonic stem cells and tissue engineering: Delivering stem cells to the clinic. J. R. Soc. Med. 98(8):346-350; 2005.
31. Vogel, G. Cell biology. Ready or not? Human ES cells head toward the clinic. Science 308(5728):1534-1538; 2005.
32. Weinand, C.; Peretti, G. M.; Adams, Jr., S. B.; Randolph, M. A.; Savvidis, E.; Gill, T. J. Healing potential of transplanted allogeneic chondrocytes of three different sources in lesions of the avascular zone of the meniscus: A pilot study. Arch. Orthop. Trauma Surg. 126(9):599-605; 2006.
33. WHO. Requirements for measles, mumps and rubella vaccine. Technical Report Series 840 (Annex 3); 1994.
34. Yang, K. G.; Saris, D. B.; Geuze, R. E.; Helm, Y. J.; Rijen, M. H.; Verbout, A. J.; Dhert, W. J.; Creemers, L. B. Impact of expansion and redifferentiation conditions on chondrogenic capacity of cultured chondrocytes. Tissue Eng. 12(9):2435-2447; 2006.